Literature DB >> 9607560

Transforming growth factor beta is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion.

G Portella1, S A Cumming, J Liddell, W Cui, H Ireland, R J Akhurst, A Balmain.   

Abstract

Transforming growth factor beta1 (TGF-beta1) regulates both cell growth and cellular plasticity and is therefore important in the molecular control of both the developmental and neoplastic processes. It has been suggested that TGF-beta1 may be a positive or negative regulator of tumorigenesis. Stimulation of tumorigenesis could be due to its action as an immunosuppressor or as an inducer of angiogenesis, or by its direct action on the cell in promoting cellular plasticity. In the current study, we provide evidence that TGF-beta1 can act directly on keratinocytes in vivo to induce the reversible epithelial-mesenchymal conversion of a malignant metastatic keratinocyte cell line. Two squamous clones from the cell line were shown to undergo a reversible conversion to a fibroblastoid phenotype after culture in 1 ng/ml TGF-beta1. The morphological conversion became apparent at 24 h post-TGF-beta treatment and was complete after another 24 h. The conversion was characterized by a rapid delocalization of E-cadherin within 6-12 h posttreatment, followed by down-regulation of E-cadherin levels by 72 h. These squamous clones spontaneously converted to a fibroblastoid phenotype after s.c. injection in nude mice. Importantly, four of four clones that had been stably transfected with a dominant negative TGF-beta type II receptor were unable to undergo this mesenchymal switch in vivo, despite the fact that all clones stably transfected with neomyocin resistance alone retained their spindle characteristics in vivo. This demonstrates that the epithelial-mesenchymal conversion event is mediated directly via the TGF-beta signaling pathway of the tumor cell per se, and that it is sufficient to significantly enhance tumorigenicity and the malignant and invasive characteristics of the tumor in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9607560

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  62 in total

Review 1.  TGF-beta signaling in mammary gland development and tumorigenesis.

Authors:  L M Wakefield; E Piek; E P Böttinger
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

2.  Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1.

Authors:  I Shin; A V Bakin; U Rodeck; A Brunet; C L Arteaga
Journal:  Mol Biol Cell       Date:  2001-11       Impact factor: 4.138

Review 3.  Transforming growth factor-beta, basement membrane, and epithelial-mesenchymal transdifferentiation: implications for fibrosis in kidney disease.

Authors:  P J Stahl; D Felsen
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

Review 4.  TGF-beta antagonists: why suppress a tumor suppressor?

Authors:  Rosemary J Akhurst
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

5.  TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion.

Authors:  Samy Lamouille; Erin Connolly; James W Smyth; Rosemary J Akhurst; Rik Derynck
Journal:  J Cell Sci       Date:  2012-03-07       Impact factor: 5.285

Review 6.  Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin axis in transforming growth factor-β-induced epithelial-mesenchymal transition.

Authors:  Samy Lamouille; Rik Derynck
Journal:  Cells Tissues Organs       Date:  2010-11-02       Impact factor: 2.481

Review 7.  The skinny on Slug.

Authors:  Stephanie H Shirley; Laurie G Hudson; Jing He; Donna F Kusewitt
Journal:  Mol Carcinog       Date:  2010-10       Impact factor: 4.784

8.  Zyxin is a transforming growth factor-β (TGF-β)/Smad3 target gene that regulates lung cancer cell motility via integrin α5β1.

Authors:  Nikica Mise; Rajkumar Savai; Haiying Yu; Johannes Schwarz; Naftali Kaminski; Oliver Eickelberg
Journal:  J Biol Chem       Date:  2012-07-09       Impact factor: 5.157

Review 9.  TGFβ biology in cancer progression and immunotherapy.

Authors:  Rik Derynck; Shannon J Turley; Rosemary J Akhurst
Journal:  Nat Rev Clin Oncol       Date:  2020-07-24       Impact factor: 66.675

10.  Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761.

Authors:  Erin C Connolly; Elise F Saunier; David Quigley; Minh Thu Luu; Angela De Sapio; Byron Hann; Jonathan M Yingling; Rosemary J Akhurst
Journal:  Cancer Res       Date:  2011-01-31       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.